NCT07355075Phase 2, phase 3Recruiting

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

Study sponsor: Turn Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-01-20Estimated
Enrollment · participants190Estimated
Source updated2026-09-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in Investigator Global Assessment (IGA) at Week 8. After: Measure: vIGA-AD Success at Week 4 Measure: EASI-75 at Week 4 Measure: EASI-90 at Week 8 Measure: EASI-100 at Week 8.

Planned enrollment increased by 80 participants

Before: 110 participants (planned). After: 190 participants (planned).

Primary completion date changed

Before: 10 Jul 2026. After: 20 Jan 2027.

Phase changed

Before: PHASE2. After: PHASE2, PHASE3.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in Eczema Area and Severity (EASI). After: Measure: Change in Investigator Global Assessment (IGA) at Week 8.

Planned enrollment increased by 10 participants

Before: 100 participants (planned). After: 110 participants (planned).

Primary completion date changed

Before: 31 May 2026. After: 10 Jul 2026.

Check registry source